LUND, Sweden, June 17, 2026
Hamlet BioPharma AB has reached a major clinical development milestone with the successful completion of a pre-initiation visit in Prague, Czech Republic, for the upcoming Phase III clinical trial of Alpha1H, its innovative treatment candidate for non-muscle invasive bladder cancer (NMIBC). The visit was conducted at the Department of Urology at Charles University, led by internationally recognized bladder cancer expert Professor Marek Babjuk, whose team previously conducted the successful Phase II study of Alpha1H. The Phase III program is expected to play a pivotal role in advancing the therapy toward potential commercialization and broad clinical adoption. As bladder cancer continues to represent one of the most costly and recurrent forms of cancer globally, the advancement of Alpha1H into late-stage development highlights growing momentum behind a novel therapeutic approach designed to improve outcomes while reducing treatment burden for patients.
Phase III Program Builds on Successful Clinical Results
The upcoming Phase III study follows encouraging results from the previously completed Phase II trial, which demonstrated Alpha1H’s potential as a therapeutic option for patients with NMIBC. The Prague-based clinical team has extensive experience in bladder cancer research and has played a significant role in evaluating innovative treatment strategies for patients at risk of recurrence and disease progression. The new trial is designed to further assess the efficacy and safety of Alpha1H while providing longer-term follow-up and direct comparisons against current standards of care.
Importantly, the study has been developed based on extensive scientific and clinical evaluations conducted by the U.S. Food and Drug Administration (FDA), including reviews of published clinical findings and the therapy’s unique mechanism of action. This regulatory engagement strengthens confidence in the program and supports the continued advancement of Alpha1H toward potential future approval.
Addressing a Major Unmet Need in Bladder Cancer
Advertisement
Bladder cancer remains one of the most significant challenges in urologic oncology, with high recurrence rates contributing to substantial healthcare costs and patient burden. In the United States, bladder cancer is considered among the most expensive cancers to manage, largely due to the need for continuous monitoring, repeated procedures, and treatment of recurrent disease. Although several treatment options are available, many patients continue to experience disease recurrence and progression, creating demand for more effective and less toxic therapies.
Alpha1H is being developed as a differentiated therapeutic approach with the potential to improve disease control while preserving quality of life. Researchers believe the treatment may offer a novel mechanism capable of targeting cancer cells while minimizing damage to healthy tissues, an important consideration in long-term bladder cancer management.
Strengthening Commercial and Clinical Potential
The initiation of Phase III development significantly enhances the commercial outlook for Alpha1H and positions Hamlet BioPharma to address a large and growing global market opportunity. The collaboration with Charles University and Professor Babjuk’s internationally respected research team provides access to extensive clinical expertise and a well-established infrastructure for conducting advanced bladder cancer trials. Company leadership emphasized that the study will generate critical data regarding long-term patient outcomes and comparative effectiveness against existing treatment options.
By combining strong clinical foundations with ongoing regulatory engagement and international scientific collaboration, Hamlet BioPharma is advancing a therapy that could potentially reshape the treatment landscape for patients with NMIBC. As the company moves toward late-stage clinical evaluation, Alpha1H continues to emerge as one of the most closely watched investigational therapies in bladder cancer, offering hope for improved outcomes in a disease where recurrence remains a persistent challenge.
Source: Hamlet BioPharma press release
